{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:29:00Z","timestamp":1794245340172,"version":"4.9.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA271410"],"award-info":[{"award-number":["U01CA271410"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA15083"],"award-info":[{"award-number":["P30CA15083"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paula and Rodger Riney, Family Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Investigating venetoclax (VTX) resistance in multiple myeloma (MM) is crucial for the development of novel therapeutic strategies to tackle resistance. We conducted a multi-omic characterization of established VTX-resistant isogenic human myeloma cell lines (HMCL) and primary MM patient samples pre- and post-VTX treatment. Transcriptomic and proteomic analysis revealed that resistance was largely associated with BCL-2 family protein dysregulation, including upregulation of anti-apoptotic proteins such as MCL-1, BCL-XL, BCL-2, and downregulation of pro-apoptotic members. Notably, the re-introduction of BIM into resistant cells restored VTX sensitivity and synergized with MCL-1 inhibitors. Upstream signaling pathways, including growth factor receptor tyrosine kinase (RTK) and phosphoinositide-3-kinase (PI3K) were implicated in this dysregulation. Simultaneous inhibition of MCL-1, BCL-XL, and upstream PI3K, RTK (FGF, EGF, and IGF1) mediated signaling enhanced VTX sensitivity. Post-translational modifications of MCL-1, particularly its stabilization via acetylation and phosphorylation, were investigated, although their inhibition only marginally increased VTX sensitivity. Lastly, the inhibition of AURKA and mitochondrial respiration also improved VTX sensitivity in some resistant HMCLs. Our findings suggest that combining VTX with MCL-1 and BCL-XL inhibitors or PIK3\/RTK inhibitors holds potential for overcoming resistance. The study illustrates the importance of understanding molecular determinants of resistance to develop tailored therapeutic strategies.<\/jats:p>","DOI":"10.1038\/s41408-025-01215-x","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T06:46:16Z","timestamp":1738737976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7130-0340","authenticated-orcid":false,"given":"Rodrigo","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Bruins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ahmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0383-9533","authenticated-orcid":false,"given":"Cecilia","family":"de Bonolo Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3860-4830","authenticated-orcid":false,"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-7098","authenticated-orcid":false,"given":"Mariano","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Darvish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Meermeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran K.","family":"Mangalaparthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Kandasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Ahmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Erin","family":"Wiedmeier-Nutor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9943-6127","authenticated-orcid":false,"given":"Akhilesh","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4024-8225","authenticated-orcid":false,"given":"Marta","family":"Chesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"1215_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3324\/haematol.2021.280201","volume":"107","author":"I Ferrarini","year":"2022","unstructured":"Ferrarini I, Rigo A, Visco C. The mitochondrial anti-apoptotic dependencies of hematological malignancies: from disease biology to advances in precision medicine. Haematologica. 2022;107:790\u2013802.","journal-title":"Haematologica"},{"key":"1215_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fonc.2018.00533","volume":"8","author":"A Slomp","year":"2018","unstructured":"Slomp A, Peperzak V. Role and regulation of pro-survival BCL-2 proteins in multiple myeloma. Front Oncol. 2018;8:533.","journal-title":"Front Oncol"},{"key":"1215_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.15171\/apb.2019.024","volume":"9","author":"R Jan","year":"2019","unstructured":"Jan R, Chaudhry GE. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharm Bull. 2019;9:205\u201318.","journal-title":"Adv Pharm Bull"},{"key":"1215_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395\u2013417.","journal-title":"Nat Rev Clin Oncol"},{"key":"1215_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","volume":"22","author":"ST Diepstraten","year":"2022","unstructured":"Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022;22:45\u201364.","journal-title":"Nat Rev Cancer"},{"key":"1215_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1215_CR7","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225\u201336.","journal-title":"N Engl J Med"},{"key":"1215_CR8","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1630\u201342.","journal-title":"Lancet Oncol"},{"key":"1215_CR9","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/blood.2020007899","volume":"137","author":"VA Gupta","year":"2021","unstructured":"Gupta VA, Barwick BG, Matulis SM, Shirasaki R, Jaye DL, Keats JJ, et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood. 2021;137:3604\u201315.","journal-title":"Blood"},{"key":"1215_CR10","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105\u2013e18.","journal-title":"Lancet Oncol"},{"key":"1215_CR11","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"1215_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519\u201327.","journal-title":"Lancet"},{"key":"1215_CR13","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl J Med. 2012;366:1782\u201391.","journal-title":"N. Engl J Med"},{"key":"1215_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21:1317\u201330.","journal-title":"Lancet Oncol"},{"key":"1215_CR15","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017;130:2401\u20139.","journal-title":"Blood"},{"key":"1215_CR16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2015.184","volume":"30","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016;30:761\u20134.","journal-title":"Leukemia"},{"key":"1215_CR17","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/bjc.2016.49","volume":"114","author":"M Butterworth","year":"2016","unstructured":"Butterworth M, Pettitt A, Varadarajan S, Cohen GM. BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells. Br J Cancer. 2016;114:638\u201341.","journal-title":"Br J Cancer"},{"key":"1215_CR18","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/s41375-022-01627-9","volume":"36","author":"YJ Thus","year":"2022","unstructured":"Thus YJ, Eldering E, Kater AP, Spaargaren M. Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma. Leukemia. 2022;36:2165\u201376.","journal-title":"Leukemia"},{"key":"1215_CR19","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood.2021014304","volume":"140","author":"D Thomalla","year":"2022","unstructured":"Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling CD, et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022;140:2113\u201326.","journal-title":"Blood"},{"key":"1215_CR20","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","volume":"104","author":"E Tausch","year":"2019","unstructured":"Tausch E, Close W, Dolnik A, Bloehdorn J, Chyla B, Bullinger L, et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019;104:e434\u2013e7.","journal-title":"Haematologica"},{"key":"1215_CR21","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2022016040","volume":"140","author":"R Thijssen","year":"2022","unstructured":"Thijssen R, Tian L, Anderson MA, Flensburg C, Jarratt A, Garnham AL, et al. Single-cell multiomics reveal the scale of multi-layered adaptations enabling CLL relapse during venetoclax therapy. Blood. 2022;140:2127\u2013214.","journal-title":"Blood"},{"key":"1215_CR22","doi-asserted-by":"publisher","first-page":"2485-","DOI":"10.1182\/blood.V110.11.2485.2485","volume":"110","author":"PL Bergsagel","year":"2007","unstructured":"Bergsagel PL, Kuehl WM, Chesi M, Keats JJ. A simple and reliable method to verify the authenticity and purity of human myeloma cell lines. Blood. 2007;110:2485-.","journal-title":"Blood"},{"key":"1215_CR23","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.3390\/cancers15133302","volume":"15","author":"KK Mangalaparthi","year":"2023","unstructured":"Mangalaparthi KK, Patel K, Khan AA, Nair B, Kumar RV, Prasad TSK, et al. Molecular characterization of esophageal squamous cell carcinoma using quantitative proteomics. Cancers. 2023;15:3302.","journal-title":"Cancers"},{"key":"1215_CR24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, et al. SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteom Bioinform. 2022;20:587\u201396.","journal-title":"Genomics Proteom Bioinform"},{"key":"1215_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109988","volume":"37","author":"K Shimizu","year":"2021","unstructured":"Shimizu K, Gi M, Suzuki S, North BJ, Watahiki A, Fukumoto S, et al. Interplay between protein acetylation and ubiquitination controls MCL1 protein stability. Cell Rep. 2021;37:109988.","journal-title":"Cell Rep"},{"key":"1215_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","volume":"27","author":"VV Senichkin","year":"2020","unstructured":"Senichkin VV, Streletskaia AY, Gorbunova AS, Zhivotovsky B, Kopeina GS. Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 2020;27:405\u201319.","journal-title":"Cell Death Differ"},{"key":"1215_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41419-020-02760-y","volume":"11","author":"X Wu","year":"2020","unstructured":"Wu X, Luo Q, Liu Z. Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options. Cell Death Dis. 2020;11:556.","journal-title":"Cell Death Dis"},{"key":"1215_CR28","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/cells10030554","volume":"10","author":"C Choi","year":"2021","unstructured":"Choi C, Lee GH, Son A, Yoo GS, Yu JI, Park HC. Downregulation of Mcl-1 by panobinostat potentiates proton beam therapy in hepatocellular carcinoma cells. Cells. 2021;10:554.","journal-title":"Cells"},{"key":"1215_CR29","doi-asserted-by":"publisher","first-page":"e1316-e","DOI":"10.1038\/cddis.2014.281","volume":"5","author":"J Yan","year":"2014","unstructured":"Yan J, Zhong N, Liu G, Chen K, Liu X, Su L, et al. Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells. Cell Death Dis. 2014;5:e1316-e.","journal-title":"Cell Death Dis"},{"key":"1215_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature08646","volume":"463","author":"M Schwickart","year":"2010","unstructured":"Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010;463:103\u20137.","journal-title":"Nature"},{"key":"1215_CR31","doi-asserted-by":"crossref","unstructured":"Slomp A, Moesbergen LM, Eldering E, Kersten MJ, Minnema MC, Peperzak V. Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells. Cell Death Dis. 2021;12:229.","DOI":"10.1038\/s41419-020-03351-7"},{"key":"1215_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01305-3","volume":"20","author":"R Du","year":"2021","unstructured":"Du R, Huang C, Liu K, Li X, Dong Z. Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol Cancer. 2021;20:15.","journal-title":"Mol Cancer"},{"key":"1215_CR33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00018-012-1073-7","volume":"70","author":"AS Nikonova","year":"2013","unstructured":"Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL Jr, Golemis EA. Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci. 2013;70:661\u201387.","journal-title":"Cell Mol Life Sci"},{"key":"1215_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15051-z","volume":"11","author":"R Bajpai","year":"2020","unstructured":"Bajpai R, Sharma A, Achreja A, Edgar CL, Wei C, Siddiqa AA, et al. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat Commun. 2020;11:1228.","journal-title":"Nat Commun"},{"key":"1215_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3383-5","volume":"17","author":"SK Tahir","year":"2017","unstructured":"Tahir SK, Smith ML, Hessler P, Rapp LR, Idler KB, Park CH, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer. 2017;17:399.","journal-title":"BMC Cancer"},{"key":"1215_CR36","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","volume":"22","author":"X Niu","year":"2016","unstructured":"Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, et al. Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clin Cancer Res. 2016;22:4440\u201351.","journal-title":"Clin Cancer Res"},{"key":"1215_CR37","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.bbrc.2011.08.118","volume":"413","author":"P Gomez-Bougie","year":"2011","unstructured":"Gomez-Bougie P, M\u00e9noret E, Juin P, Dousset C, Pellat-Deceunynck C, Amiot M. Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1\/USP9X interaction. Biochem Biophys Res Commun. 2011;413:460\u20134.","journal-title":"Biochem Biophys Res Commun"},{"key":"1215_CR38","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1101\/gad.302497.117","volume":"31","author":"PK Singh","year":"2017","unstructured":"Singh PK, Roukounakis A, Frank DO, Kirschnek S, Das KK, Neumann S, et al. Dynein light chain 1 induces assembly of large Bim complexes on mitochondria that stabilize Mcl-1 and regulate apoptosis. Genes Dev. 2017;31:1754\u201369.","journal-title":"Genes Dev"},{"key":"1215_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-022-01296-8","volume":"9","author":"S Khan","year":"2023","unstructured":"Khan S, Kellish P, Connis N, Thummuri D, Wiegand J, Zhang P, et al. Co-targeting BCL-X(L) and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell Death Discov. 2023;9:1.","journal-title":"Cell Death Discov"},{"key":"1215_CR40","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","volume":"8","author":"HE Ramsey","year":"2018","unstructured":"Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8:1566\u201381.","journal-title":"Cancer Discov"},{"key":"1215_CR41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10020-022-00565-7","volume":"29","author":"T Zhao","year":"2023","unstructured":"Zhao T, He Q, Xie S, Zhan H, Jiang C, Lin S, et al. A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells. Mol Med. 2023;29:10.","journal-title":"Mol Med"},{"key":"1215_CR42","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.yexcr.2014.02.010","volume":"322","author":"JM Eichhorn","year":"2014","unstructured":"Eichhorn JM, Alford SE, Sakurikar N, Chambers TC. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival. Exp Cell Res. 2014;322:415\u201324.","journal-title":"Exp Cell Res"},{"key":"1215_CR43","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","volume":"39","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ, et al. Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol. 2021;39:3602\u201312.","journal-title":"J Clin Oncol"},{"key":"1215_CR44","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/leu.2015.350","volume":"30","author":"SM Matulis","year":"2016","unstructured":"Matulis SM, Gupta VA, Nooka AK, Hollen HV, Kaufman JL, Lonial S, et al. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia. 2016;30:1086\u201393.","journal-title":"Leukemia"},{"key":"1215_CR45","doi-asserted-by":"crossref","unstructured":"Roufayel R, Younes K, Al-Sabi A, Murshid N. BH3-only proteins Noxa and Puma are key regulators of induced apoptosis. Life (Basel). 2022;12:256.","DOI":"10.3390\/life12020256"},{"key":"1215_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01614-z","volume":"20","author":"X Yue","year":"2020","unstructured":"Yue X, Chen Q, He J. Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. Cancer Cell Int. 2020;20:524.","journal-title":"Cancer Cell Int"},{"key":"1215_CR47","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1182\/bloodadvances.2023012298","volume":"8","author":"S Deng","year":"2024","unstructured":"Deng S, Derebail S, Weiler VJ, Fong Ng J, Maroto-Martin E, Chatterjee M, et al. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies. Blood Adv. 2024;8:4025\u201334.","journal-title":"Blood Adv"},{"key":"1215_CR48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-020-01007-9","volume":"13","author":"A Bolomsky","year":"2020","unstructured":"Bolomsky A, Vogler M, Kose MC, Heckman CA, Ehx G, Ludwig H, et al. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. J Hematol Oncol. 2020;13:173.","journal-title":"J Hematol Oncol"},{"key":"1215_CR49","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/s43018-024-00814-0","volume":"5","author":"U Rauh","year":"2024","unstructured":"Rauh U, Wei G, Serrano-Wu M, Kosmidis G, Kaulfuss S, Siegel F, et al. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nat Cancer. 2024;5:1479\u201393.","journal-title":"Nat Cancer"},{"key":"1215_CR50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021;14:67.","journal-title":"J Hematol Oncol"},{"key":"1215_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7:51.","journal-title":"Signal Transduct Target Ther"},{"key":"1215_CR52","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3324\/haematol.2018.205534","volume":"105","author":"L Han","year":"2020","unstructured":"Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, et al. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2020;105:697\u2013707.","journal-title":"Haematologica"},{"key":"1215_CR53","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-10-3012","volume":"17","author":"L Santo","year":"2011","unstructured":"Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, et al. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011;17:3259\u201371.","journal-title":"Clin Cancer Res"},{"key":"1215_CR54","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1158\/1078-0432.CCR-18-0440","volume":"25","author":"JW Lee","year":"2019","unstructured":"Lee JW, Parameswaran J, Sandoval-Schaefer T, Eoh KJ, Yang DH, Zhu F, et al. Combined aurora kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2019;25:3430\u201342.","journal-title":"Clin Cancer Res"},{"key":"1215_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-1072-y","volume":"20","author":"Y Yang","year":"2020","unstructured":"Yang Y, Ding L, Zhou Q, Fen L, Cao Y, Sun J, et al. Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells. Cancer Cell Int. 2020;20:9.","journal-title":"Cancer Cell Int"},{"key":"1215_CR56","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41419-020-02867-2","volume":"11","author":"A Roca-Portoles","year":"2020","unstructured":"Roca-Portoles A, Rodriguez-Blanco G, Sumpton D, Cloix C, Mullin M, Mackay GM, et al. Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. Cell Death Dis. 2020;11:616.","journal-title":"Cell Death Dis"},{"key":"1215_CR57","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10:536\u201351.","journal-title":"Cancer Discov"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01215-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01215-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01215-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T08:55:29Z","timestamp":1738745729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01215-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01215-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PLB has served as a consultant for Pfizer, Novartis, GSK, Janssen, and Oncopeptides. RF has served as a consultant for AbbVie, Amgen, Bayer, BMS\/Celgene, GSK, H3 Therapeutics, Janssen, Juno, Karyopharm, Kite, Merck, Novartis, Oncopeptides, Oncotracker, Pfizer, Pharmacyclics, Regeneron, Sanofi, Takeda; and has served as an advisory board member for Adaptive Biotechnologies, Caris Life Sciences and OncoMyx. No disclosures were reported by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}